1. Overview
  2. All Stocks
  3. CG Oncology Inc. Common stock

CG Oncology (CGON.US) Price Target 2026/2027: 25% Upside – Rating and Stock Analysis

72.47
Analysis framework by , founder of TradeDesk · Data: EODHD, official filings (SEC) · Updated
Share this analysis:

CG Oncology Price Target 2026: Analysts See 26% Upside

The average price target for CG Oncology is $91.08. This price target represents the analysts' view of the stock price over the next 12 months. The stock may be undervalued, because the price target is higher than the current price. The stock is 25.69% below the target, which can point to potential returns within the next 12 months if the analysts' view proves right. Also consider the stock's valuation ratios such as P/E, P/S and P/B, plus the technical analysis further down the page, for the full picture.

Is CG Oncology overvalued or undervalued?

CG Oncology is currently undervalued with a gap of 25.7% relative to the price target.


The current price is $72.47, which places CG Oncology in the undervalued category. The stock is considered undervalued when the price is below $81.97, and overvalued when the price exceeds $100.19.


The fair value range is defined as ±10% of the price target, because price targets are estimates rather than exact values. For CG Oncology, the fair value range lies between $81.97 and $100.19.


See the full price target analysis for CG Oncology →

↑ Back to navigation

Analyst Ratings for CG Oncology stock in 2026: Buy

10 analysts cover CG Oncology. There is broad agreement on a positive view — 90% recommend buying. The average price target is $91.08, which gives an upside of 25.7% from the current price.

Consensus: Buy (4.40/5)
Strong Buy
5 (50%)
Buy
4 (40%)
Hold
1 (10%)
Strong Sell Sell Hold Buy Strong Buy
4.40 out of 5 based on 10 analysts
↑ Back to navigation

About CG Oncology – Biotechnology

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Dallas, Texas. Read more about the company

Key Figures for CG Oncology

$ 6.9B Market cap
$ 6.2M Revenue
Biotechnology Industry
- P/E
1,106.44 P/S
6.74 P/B
United States Listed on exchange
cgoncology.com Website
Healthcare Sector

What kind of stock is CG Oncology?

Momentum stock

CG Oncology is classified as a momentum stock with a momentum score in the top 13% of all stocks. The price has risen 0.0% over the long term.

Score Overview for CG Oncology

💰 Value Score 5/100 (Very Low)
⭐ Quality Score 17/100 (Very Low)
🚀 Momentum Score 87/100 (Very High)
📊 Total Score 36/100

⚠️ 3 red flags identified 1 critical

Our analysis has identified 3 potential risk factors in CG Oncology that investors should be aware of.

⚠️ Weak financial health: The Piotroski score is only 3/9 – the company shows signs of weakened profitability, liquidity or capital structure.
🚨 Negative return on equity: ROE is -26.4% – the company is generating a negative return for shareholders.
⚠️ High short interest: 13.1% of the shares are sold short – many professional investors are betting on price declines.

📈 Valuation

The P/S ratio is 1,106.4 (high — the market pays a premium for the revenue). The P/B ratio is 6.7.

🏦 Financial Health

The Piotroski score is 3 out of 9 — weak financial health, be careful. Altman Z2 is 22.46 (healthy balance sheet — low risk). The debt-to-equity ratio (D/E) is 2.9% — low debt, a solid balance sheet.

🚀 Momentum & Short Interest

Short interest is 13.09% — very high, the market is skeptical.

↑ Back to navigation

CG Oncology Short Selling 2026: 13.1% Sold Short

Very high short interest: 13.1% of the free float
Short % of free float
13.1%
Assessment
Very high short interest
Short squeeze risk
High
Data source
SEC
Updated daily
The stock has a very high share of short selling. Between 10-20% of the freely traded shares are sold short, which points to considerable bearish sentiment. A positive earnings report or unexpectedly good news can trigger a short squeeze with sharp price gains.

What does this mean for you as an investor?
A short interest of 13.1% means that 13.1% of the freely traded shares in CG Oncology have been borrowed and sold by investors betting on falling prices. On positive surprises (e.g. a strong earnings report), short sellers can be forced to buy back shares quickly to close their positions, which can cause a short squeeze with sharp price gains in a short time.

Data is updated daily based on official filings with the SEC.
Short Interest Scale
0% 2% 5% 10% 20%+
Low Moderate High Very High Extreme
▲
13.1%

↑ Back to navigation

When Does CG Oncology Report Earnings?

The next earnings date for CG Oncology is not yet available. Check the company's investor calendar for more information.



↑ Back to navigation

Technical Analysis of CG Oncology 2026 – Signal: Buy

Overall Technical Signal: Buy

Based on trend analysis (SMA50/SMA200) and MACD trend (positive/negative on a daily + weekly basis). Updated September 23, 2026.

Trend Analysis of CG Oncology Inc. Common stock

CG Oncology Inc. Common stock is in a short-term uptrend. The price of $77.74 is 3.5% above the 20-day average ($75.09). Medium term, the picture is positive: the price is 4.7% above the 50-day average ($74.24). Long term, the stock is 23.8% above the 200-day average ($62.81), which confirms a long-term uptrend.

Golden Cross: The 50-day average (74.24) is above the 200-day average (62.81), which is a classic bullish signal for CG Oncology Inc. Common stock.

Is CG Oncology Inc. Common stock overbought or oversold?

CG Oncology Inc. Common stock has an RSI of 57.8. The stock shows positive momentum in the upper part of the neutral zone.

MACD Analysis for CG Oncology Inc. Common stock

Daily MACD: MACD is positive (0.368), which means the short-term trend is bullish (the 12-day EMA is above the 26-day EMA). MACD is above the signal line (0.059) by 0.309, which confirms rising momentum in the uptrend.

Weekly MACD: MACD5 is positive (4.994), which indicates a broader bullish long-term trend. MACD5 is below the signal line (5.278) by 0.284, which suggests the long-term momentum is fading – the positive trend could come under pressure.

Overall MACD assessment: Both the daily and weekly trend are bullish (MACD positive). However, momentum shows signs of weakening on a weekly basis. Watch whether the trend holds.

Risk Profile for CG Oncology Inc. Common stock

CG Oncology Inc. Common stock has an annual standard deviation of 56.1%, which classifies the stock as Speculative. Sizeable price swings are normal, and the stock requires a higher risk tolerance.

Overall Technical Conclusion for CG Oncology Inc. Common stock

Trend: Neutral/mixed.

MACD trend (zero line): Daily bullish (0.368). Weekly bullish (4.994).

MACD momentum (signal): Daily rising. Weekly falling.

RSI: 57.8 – neutral.

Technical signal: Buy

The broader trend is positive and MACD supports the picture. Consider buying with a stop-loss below the nearest support level.

↑ Back to navigation

Frequently Asked Questions About CG Oncology stock in 2026

Should you buy CG Oncology stock now?
Yes, the technical signal for CG Oncology is currently BUY. CG Oncology trades at $72.47 as of 9/23/2026. The overall technical signal is: Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 0.368 with rising momentum (signal: 0.059); RSI is at 57.8 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $91.08 points to 25.7% upside. This is a technical observation based on current data, not investment advice.
What is the price target for CG Oncology stock?
The average analyst price target for CG Oncology is $91.08. The current price is $72.47, which gives an upside of 25.7%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $81.97 and $100.19.
Is CG Oncology a dividend stock?
No, CG Oncology does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of CG Oncology stock?
CG Oncology is rated as a stock in the risk category Speculative. the annual standard deviation is 56.1%, which classifies the stock as Speculative.
Is CG Oncology overvalued?
No, CG Oncology is considered undervalued based on the analyst price target (25.7% upside). CG Oncology has the following valuation ratios: a P/S ratio of 1,106.4, a P/B ratio of 6.7. The analyst price target suggests that the stock is undervalued by 25.7%.
Is CG Oncology overbought?
No, CG Oncology is not overbought. RSI is at 57.8 (neutral zone). The technical indicators show: RSI is at 57.8 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 3.5% below the 20-day average (short-term downtrend). In addition, MACD is positive with rising momentum (bullish).
When is the next CG Oncology earnings report?
The date of the next earnings report for CG Oncology has not been published yet. Check the company's investor calendar for updates.
Is CG Oncology shorted?
Yes, CG Oncology is shorted with 13.1% of the free float sold short. This is a very high level of short selling, which points to considerable bearish sentiment. A positive earnings report or unexpectedly good news can trigger a short squeeze with sharp price gains. Data is updated daily based on official filings with the SEC.
Are insiders buying CG Oncology stock?
There is currently no registered insider trading for CG Oncology.
Is CG Oncology a good stock?
Based on our total score, CG Oncology is rated as a poor stock with a total score of 36 out of 100. The stock scores below average on value, quality and momentum – it sits at the lower end of the market. The score is made up of Value: 5/100, Quality: 17/100, Momentum: 87/100. In addition: analysts see 25.7% upside to the price target; technical signal: Buy. Whether CG Oncology is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for CG Oncology stock?
The outlook for CG Oncology based on current data: the average analyst price target is $91.08 (+25.7%). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is CG Oncology stock falling?
CG Oncology is falling right now. The technical indicators show: the price is 3.5% below the 20-day average; MACD is positive with rising momentum (bullish signal); short interest is 13.1% (high – many are betting on a decline). For the latest context, see our technical analysis, insider section and news overview above.
How high can CG Oncology go?
The average analyst price target for CG Oncology is $91.08, which corresponds to a potential gain of 25.7% from the current price of $72.47. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can CG Oncology fall?
We lack enough history to give a specific floor for CG Oncology. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does CG Oncology do?
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, ... The company belongs to the Healthcare sector, more specifically the Biotechnology industry, is headquartered in United States, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate CG Oncology as an investment.
Did CG Oncology raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from CG Oncology. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is CG Oncology making money or losing money?
We have no current profitability data for CG Oncology. See the latest report in the earnings history above.
Can CG Oncology go bankrupt?
The bankruptcy risk of CG Oncology is rated as low. Altman Z2 (a model for assessing financial distress) is 22.46 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 3 — which is weak. Debt relative to equity is 3% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does CG Oncology have a lot of debt?
No, CG Oncology has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 3%. For the healthcare sector, anything below 80% counts as low debt. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
↑ Back to navigation

Other Stocks in Healthcare

Compare CG Oncology with other stocks in the healthcare sector. Click a stock to see its technical analysis, insider trading and key figures.

See all 105 stocks in the Healthcare sector

Explore More